Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery Patients

Maurizio Ferratini; Vittorino Ripamonti; Serge Masson; Paola Grati; Vittorio Racca; Ivan Cuccovillo; Elena Raimondi; Soccorso Capomolla; Claudio Macchi; Paolo Coruzzi; Tarcisio Vago; Maria Gaetana Calvo; Alberto Mantovani; Roberto Latini

doi:10.1097/hcr.0b013e31823be0f4

Related publications

Article2019

Pentraxin 3 in Cardiovascular Disease

Giuseppe Ristagno, Francesca Fumagalli, Barbara Bottazzi, Alberto Mantovani, Davide Olivari, Deborah Novelli, Roberto Latini

Article2020

Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention

Mahesh V. Madhavan, Ajay J. Kirtane, Björn Redfors, Philippe Généreux, Ori Ben‐Yehuda, Tullio Palmerini, Umberto Benedetto, Giuseppe Biondi‐Zoccai, Pieter C. Smits, Clemens von Birgelen, Roxana Mehran, Thomas McAndrew, Patrick W. Serruys, Martin B. Leon, Stuart J. Pocock, Gregg W. Stone

Journal of the American College of Cardiology

Article2012

Short- and Long-Term Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention with Stenting for Acute Myocardial Infarction Complicated by Cardiogenic Shock

Milena Soriano Marcolino, Cihan Şimşek, Sanneke P.M. de Boer, Ron T. van Domburg, Robert‐Jan van Geuns, Peter de Jaegere, K. Martijn Akkerhuis, Joost Daemen, Patrick W. Serruys, Eric Boersma

Cardiology

Article2011

Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications

Franco Lerzo, Giuseppe Peri, Andrea Doni, Paola Bocca, Fabio Morandi, Angela Pistorio, Anna Maria Carleo, Alberto Mantovani, Vito Pistoia, Ignazia Prigione

Article2023

#4779 CARDIAC BIOMARKERS FOR THE PREDICTION OF INCIDENT MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS STARTING HAEMODIALYSIS: A REAL-WORLD ANALYSIS

Garry McDowell, Louise Moore, Benjamin J. R. Buckley, Philip Austin, Professor Gregory Lip, Anirudh Rao

Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery Patients

Abstract

Discussion(0)

Related publications

Pentraxin 3 in Cardiovascular Disease

Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention

Short- and Long-Term Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention with Stenting for Acute Myocardial Infarction Complicated by Cardiogenic Shock

Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications

#4779 CARDIAC BIOMARKERS FOR THE PREDICTION OF INCIDENT MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS STARTING HAEMODIALYSIS: A REAL-WORLD ANALYSIS

Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery Patients

Abstract

Discussion(0)

Related publications

Pentraxin 3 in Cardiovascular Disease

Stent-Related Adverse Events &gt;1 Year After Percutaneous Coronary Intervention

Short- and Long-Term Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention with Stenting for Acute Myocardial Infarction Complicated by Cardiogenic Shock

Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications

#4779 CARDIAC BIOMARKERS FOR THE PREDICTION OF INCIDENT MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS STARTING HAEMODIALYSIS: A REAL-WORLD ANALYSIS

Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention